Money Magnet Immunocore kicks off Trial for Eye Melanoma

31/03/2016 - 2 minutes

Immunocore (UK) has enrolled its first patient for a phase I trial that will test its ImmTAC as a standalone therapy for uveal melanoma, the most common eye cancer.

immunocore_tcr_immtac_uveal_melanomaImmunocore is famous for having raised the biggest European Private round ever (€300M), and so it’s no wonder that if often makes our tops here at Labiotech – from billion euro Biotechs in Europe, to the only real unicorns and the 10 hot Biotechs to watch in 2016.

It is now starting phase I/IIa trials for uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, there are no effective treatments on the market for this debilitating disease.

Uveal melanoma is just one of the applications for Immunocore’s leading candidate, IMCgp100. It is also in a phase I/IIa trials for the treatment of late stage metastatic melanoma.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following: